Fundamental Mechanisms of Immune Checkpoint Blockade Therapy

Sharma, 2015, The future of immune checkpoint therapy, Science, 348, 56, 10.1126/science.aaa8172

Topalian, 2015, Immune checkpoint blockade: a common denominator approach to cancer therapy, Cancer Cell, 27, 450, 10.1016/j.ccell.2015.03.001

Pardoll, 2012, The blockade of immune checkpoints in cancer immunotherapy, Nat Rev Cancer, 12, 252, 10.1038/nrc3239

Dunn, 2004, The three Es of cancer immunoediting, Ann Rev Immunol, 22, 329, 10.1146/annurev.immunol.22.012703.104803

Tang, 2018, Comprehensive analysis of the clinical immuno-oncology landscape, Ann Oncol, 29, 84, 10.1093/annonc/mdx755

Sharma, 2017, Primary, adaptive, and acquired resistance to cancer immunotherapy, Cell, 168, 707, 10.1016/j.cell.2017.01.017

Ribas, 2018, Cancer immunotherapy using checkpoint blockade, Science, 359, 1350, 10.1126/science.aar4060

Walunas, 1994, CTLA-4 can function as a negative regulator of T cell activation, Immunity, 1, 405, 10.1016/1074-7613(94)90071-X

Brunner, 1999, CTLA-4-Mediated inhibition of early events of T cell proliferation, J Immunol, 162, 5813, 10.4049/jimmunol.162.10.5813

Linsley, 1994, Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors, Immunity, 1, 793, 10.1016/S1074-7613(94)80021-9

Linsley, 1991, CTLA-4 is a second receptor for the B cell activation antigen B7, J Exp Med, 174, 561, 10.1084/jem.174.3.561

van der Merwe, 1997, CD80 (B7-1) binds both CD28 and CTLA-4 with a low affinity and very fast kinetics, J Exp Med, 185, 393, 10.1084/jem.185.3.393

Lanier, 1995, CD80 (B7) and CD86 (B70) provide similar costimulatory signals for T cell proliferation, cytokine production, and generation of CTL, J Immunol, 154, 97, 10.4049/jimmunol.154.1.97

Egen, 2002, Cytotoxic T lymphocyte antigen-4 accumulation in the immunological synapse is regulated by TCR signal strength, Immunity, 16, 23, 10.1016/S1074-7613(01)00259-X

Pentcheva-Hoang, 2004, B7-1 and B7-2 selectively recruit CTLA-4 and CD28 to the immunological synapse, Immunity, 21, 401, 10.1016/j.immuni.2004.06.017

Kane, 2001, Akt provides the CD28 costimulatory signal for up-regulation of IL-2 and IFN-gamma but not TH2 cytokines, Nat Immunol, 2, 37, 10.1038/83144

Pages, 1994, Binding of phosphatidylinositol-3-OH kinase to CD28 is required for T-cell signalling, Nature, 369, 327, 10.1038/369327a0

Chambers, 1997, Thymocyte development is normal in CTLA-4-deficient mice, Proc Natl Acad Sci U S A, 94, 9296, 10.1073/pnas.94.17.9296

Waterhouse, 1995, Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4, Science, 270, 985, 10.1126/science.270.5238.985

Tivol, 1995, Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4, Immunity, 3, 541, 10.1016/1074-7613(95)90125-6

Bachmann, 1999, Cutting edge: lymphoproliferative disease in the absence of CTLA-4 is not T cell autonomous, J Immunol, 163, 1128, 10.4049/jimmunol.163.3.1128

Friedline, 2009, CD4+ regulatory T cells require CTLA-4 for the maintenance of systemic tolerance, J Exp Med, 206, 421, 10.1084/jem.20081811

Read, 2006, Blockade of CTLA-4 on CD4+CD25+ regulatory T cells abrogates their function in vivo, J Immunol, 177, 4376, 10.4049/jimmunol.177.7.4376

Wing, 2008, CTLA-4 control over Foxp3+ regulatory T cell function, Science, 322, 271, 10.1126/science.1160062

Jain, 2010, Dual function of CTLA-4 in regulatory T cells and conventional T cells to prevent multiorgan autoimmunity, Proc Natl Acad Sci U S A, 107, 1524, 10.1073/pnas.0910341107

Corse, 2012, Cutting edge: CTLA-4 on effector T cells inhibits in trans, J Immunol, 189, 1123, 10.4049/jimmunol.1200695

Qureshi, 2011, Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4, Science, 332, 600, 10.1126/science.1202947

Paterson, 2015, Deletion of CTLA-4 on regulatory T cells during adulthood leads to resistance to autoimmunity, J Exp Med, 212, 1603, 10.1084/jem.20141030

Doyle, 2001, Induction of cytotoxic T lymphocyte antigen 4 (CTLA-4) restricts clonal expansion of helper T cells, J Exp Med, 194, 893, 10.1084/jem.194.7.893

Egen, 2002, CTLA-4: new insights into its biological function and use in tumor immunotherapy, Nat Immunol, 3, 611, 10.1038/ni0702-611

Lenschow, 1996, CD28/B7 system of T cell costimulation, Ann Rev Immunol, 14, 233, 10.1146/annurev.immunol.14.1.233

Latchman, 2001, PD-L2 is a second ligand for PD-1 and inhibits T cell activation, Nat Immunol, 2, 261, 10.1038/85330

Freeman, 2000, Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation, J Exp Med, 192, 1027, 10.1084/jem.192.7.1027

Dong, 1999, B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion, Nat Med, 5, 1365, 10.1038/70932

Agata, 1996, Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes, Int Immunol, 8, 765, 10.1093/intimm/8.5.765

Keir, 2006, Tissue expression of PD-L1 mediates peripheral T cell tolerance, J Exp Med, 203, 883, 10.1084/jem.20051776

Yokosuka, 2012, Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2, J Exp Med, 209, 1201, 10.1084/jem.20112741

Parry, 2005, CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms, Mol Cell Biol, 25, 9543, 10.1128/MCB.25.21.9543-9553.2005

Hui, 2017, T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition, Science, 355, 1428, 10.1126/science.aaf1292

Rota, 2018, Shp-2 is dispensable for establishing T cell exhaustion and for PD-1 signaling in vivo, Cell reports, 23, 39, 10.1016/j.celrep.2018.03.026

Nishimura, 1999, Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor, Immunity, 11, 141, 10.1016/S1074-7613(00)80089-8

Nishimura, 2001, Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice, Science, 291, 319, 10.1126/science.291.5502.319

Bengsch, 2016, Bioenergetic insufficiencies due to metabolic alterations regulated by the inhibitory receptor PD-1 are an early driver of CD8(+) T cell exhaustion, Immunity, 45, 358, 10.1016/j.immuni.2016.07.008

Patsoukis, 2015, PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation, Nat Commun, 6, 6692, 10.1038/ncomms7692

Buck, 2016, Mitochondrial dynamics controls T cell fate through metabolic programming, Cell, 166, 63, 10.1016/j.cell.2016.05.035

Wherry, 2007, Molecular signature of CD8+ T cell exhaustion during chronic viral infection, Immunity, 27, 670, 10.1016/j.immuni.2007.09.006

Pauken, 2016, Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade, Science, 354, 1160, 10.1126/science.aaf2807

Philip, 2017, Chromatin states define tumour-specific T cell dysfunction and reprogramming, Nature, 545, 452, 10.1038/nature22367

Kortlever, 2017, Myc cooperates with ras by programming inflammation and immune suppression, Cell, 171, 1301, 10.1016/j.cell.2017.11.013

Kleffel, 2015, Melanoma cell-intrinsic PD-1 receptor functions promote tumor growth, Cell, 162, 1242, 10.1016/j.cell.2015.08.052

Chen, 2013, Oncology meets immunology: the cancer-immunity cycle, Immunity, 39, 1, 10.1016/j.immuni.2013.07.012

Wherry, 2011, T cell exhaustion, Nat Immunol, 12, 492, 10.1038/ni.2035

Barber, 2006, Restoring function in exhausted CD8 T cells during chronic viral infection, Nature, 439, 682, 10.1038/nature04444

Kamphorst, 2017, Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent, Science, 355, 1423, 10.1126/science.aaf0683

Ramagopal, 2017, Structural basis for cancer immunotherapy by the first-in-class checkpoint inhibitor ipilimumab, Proc Natl Acad Sci U S A, 114, E4223, 10.1073/pnas.1617941114

Dieu-Nosjean, 2008, Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures, J Clin Oncol, 26, 4410, 10.1200/JCO.2007.15.0284

Engelhard, 2018, Immune cell infiltration and tertiary lymphoid structures as determinants of antitumor immunity, J Immunol, 200, 432, 10.4049/jimmunol.1701269

Joshi, 2015, Regulatory T cells in tumor-associated tertiary lymphoid structures suppress anti-tumor T cell responses, Immunity, 43, 579, 10.1016/j.immuni.2015.08.006

Fehlings, 2017, Checkpoint blockade immunotherapy reshapes the high-dimensional phenotypic heterogeneity of murine intratumoural neoantigen-specific CD8(+) T cells, Nat Commun, 8, 562, 10.1038/s41467-017-00627-z

Wei, 2017, Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade, Cell, 170, 1120, 10.1016/j.cell.2017.07.024

Liakou, 2008, CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients, Proc Natl Acad Sci U S A, 105, 14987, 10.1073/pnas.0806075105

Carthon, 2010, Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial, Clin Cancer Res, 16, 2861, 10.1158/1078-0432.CCR-10-0569

Chen, 2009, Anti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-gamma levels in both nonmalignant and malignant prostate tissues, Proc Natl Acad Sci U S A, 106, 2729, 10.1073/pnas.0813175106

Chaput, 2017, Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab, Ann Oncol, 28, 1368, 10.1093/annonc/mdx108

Vonderheide, 2010, Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible costimulator expression on patient T cells, Clin Cancer Res, 16, 3485, 10.1158/1078-0432.CCR-10-0505

Ng Tang, 2013, Increased frequency of ICOS+ CD4 T cells as a pharmacodynamic biomarker for anti-CTLA-4 therapy, Cancer Immunol Res, 1, 229, 10.1158/2326-6066.CIR-13-0020

Simpson, 2013, Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma, J Exp Med, 210, 1695, 10.1084/jem.20130579

Selby, 2013, Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells, Cancer Immunol Res, 1, 32, 10.1158/2326-6066.CIR-13-0013

Bulliard, 2013, Activating Fc gamma receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies, J Exp Med, 210, 1685, 10.1084/jem.20130573

Du, 2018, A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy, Cell Res, 28, 416, 10.1038/s41422-018-0011-0

Peggs, 2009, Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies, J Exp Med, 206, 1717, 10.1084/jem.20082492

Romano, 2015, Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients, Proc Natl Acad Sci U S A, 112, 6140, 10.1073/pnas.1417320112

Arce Vargas, 2018, Fc effector function contributes to the activity of human anti-CTLA-4 antibodies, Cancer Cell, 33, 649, 10.1016/j.ccell.2018.02.010

Bruhns, 2009, Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses, Blood, 113, 3716, 10.1182/blood-2008-09-179754

Ribas, 2013, Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma, J Clin Oncol, 31, 616, 10.1200/JCO.2012.44.6112

Eroglu, 2015, Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab, Eur J Cancer, 51, 2689, 10.1016/j.ejca.2015.08.012

Schadendorf, 2015, Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma, J Clin Oncol, 33, 1889, 10.1200/JCO.2014.56.2736

Robert, 2014, CTLA4 blockade broadens the peripheral T-cell receptor repertoire, Clin Cancer Res, 20, 2424, 10.1158/1078-0432.CCR-13-2648

Cha, 2014, Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients, Sci Translat Med, 6, 238ra270, 10.1126/scitranslmed.3008211

Kvistborg, 2014, Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response, Sci Translat Med, 6, 254ra128, 10.1126/scitranslmed.3008918

Oh, 2017, Immune toxicities elicted by CTLA-4 blockade in cancer patients are associated with early diversification of the T-cell repertoire, Cancer Res, 77, 1322, 10.1158/0008-5472.CAN-16-2324

Hellmann, 2018, Genomic features of response to combination immunotherapy in patients with advanced non-small-cell lung cancer, Cancer Cell, 33, 843, 10.1016/j.ccell.2018.03.018

Le, 2015, PD-1 blockade in tumors with mismatch-repair deficiency, N Engl J Med, 372, 2509, 10.1056/NEJMoa1500596

Le, 2017, Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade, Science, 357, 409, 10.1126/science.aan6733

Snyder, 2014, Genetic basis for clinical response to CTLA-4 blockade in melanoma, N Engl J Med, 371, 2189, 10.1056/NEJMoa1406498

Van Allen, 2015, Genomic correlates of response to CTLA-4 blockade in metastatic melanoma, Science, 350, 207, 10.1126/science.aad0095

Yarchoan, 2017, Tumor mutational burden and response rate to PD-1 inhibition, N Engl J Med, 377, 2500, 10.1056/NEJMc1713444

Herbst, 2014, Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients, Nature, 515, 563, 10.1038/nature14011

Tumeh, 2014, PD-1 blockade induces responses by inhibiting adaptive immune resistance, Nature, 515, 568, 10.1038/nature13954

Im, 2016, Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy, Nature, 537, 417, 10.1038/nature19330

Huang, 2017, T-cell invigoration to tumour burden ratio associated with anti-PD-1 response, Nature, 545, 60, 10.1038/nature22079

Forde, 2018, Neoadjuvant PD-1 blockade in resectable lung cancer, N Engl J Med, 378, 1976, 10.1056/NEJMoa1716078

Ghoneim, 2017, De novo epigenetic programs inhibit PD-1 blockade-mediated T cell rejuvenation, Cell, 170, 142, 10.1016/j.cell.2017.06.007

Sen, 2016, The epigenetic landscape of T cell exhaustion, Science, 354, 1165, 10.1126/science.aae0491

Bengsch, 2018, Epigenomic-guided mass cytometry profiling reveals disease-specific features of exhausted CD8 T cells, Immunity, 48, 1029, 10.1016/j.immuni.2018.04.026

Spitzer, 2017, Systemic immunity is required for effective cancer immunotherapy, Cell, 168, 487, 10.1016/j.cell.2016.12.022

Iijima, 2016, Access of protective antiviral antibody to neuronal tissues requires CD4 T-cell help, Nature, 533, 552, 10.1038/nature17979

Nakanishi, 2009, CD8(+) T lymphocyte mobilization to virus-infected tissue requires CD4(+) T-cell help, Nature, 462, 510, 10.1038/nature08511

Gubin, 2014, Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens, Nature, 515, 577, 10.1038/nature13988

Loke, 2003, PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells, Proc Natl Acad Sci U S A, 100, 5336, 10.1073/pnas.0931259100

Dahan, 2015, FcgammaRs modulate the anti-tumor activity of antibodies targeting the PD-1/PD-L1 Axis, Cancer Cell, 28, 285, 10.1016/j.ccell.2015.08.004

Butte, 2007, Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses, Immunity, 27, 111, 10.1016/j.immuni.2007.05.016

Tang, 2018, PD-L1 on host cells is essential for PD-L1 blockade-mediated tumor regression, J Clin Invest, 128, 580, 10.1172/JCI96061

Lin, 2018, Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression, J Clin Invest, 128(2), 805, 10.1172/JCI96113

Juneja, 2017, PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity, J Exp Med, 214, 895, 10.1084/jem.20160801

Postow, 2015, Nivolumab and ipilimumab versus ipilimumab in untreated melanoma, N Engl J Med, 372, 2006, 10.1056/NEJMoa1414428

Larkin, 2015, Combined nivolumab and ipilimumab or monotherapy in untreated melanoma, N Engl J Med, 373, 23, 10.1056/NEJMoa1504030

Wolchok, 2013, Nivolumab plus ipilimumab in advanced melanoma, N Engl J Med, 369, 122, 10.1056/NEJMoa1302369

Curran, 2010, PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors, Proc Natl Acad Sci U S A, 107, 4275, 10.1073/pnas.0915174107

Postow, 2017, 32nd annual meeting and pre-conference programs of the society for immunotherapy of cancer (SITC 2017): part one. Pooled 3-year overall survival data from phase II and phase III trials of nivolumab (NIVO) combined with ipilimumab (IPI) in advanced melanoma, J Immunother Cancer, 5, 86

Motzer, 2018, Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma, N Engl J Med, 378, 1277, 10.1056/NEJMoa1712126

Das, 2015, Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo, J Immunol, 194, 950, 10.4049/jimmunol.1401686

Das, 2018, Early B cell changes predict autoimmunity following combination immune checkpoint blockade, J Clin Invest, 128, 715, 10.1172/JCI96798

Kamphorst, 2017, Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients, Proc Natl Acad Sci U S A, 114, 4993, 10.1073/pnas.1705327114

Daud, 2016, Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma, J Clin Invest, 126, 3447, 10.1172/JCI87324

Weber, 2016, Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial, Lancet Oncol, 17, 943, 10.1016/S1470-2045(16)30126-7

Sanchez-Paulete, 2016, Cancer immunotherapy with immunomodulatory anti-CD137 and anti-PD-1 monoclonal antibodies requires BATF3-Dependent dendritic cells, Cancer Discov, 6, 71, 10.1158/2159-8290.CD-15-0510

Salmon, 2016, Expansion and activation of CD103(+) dendritic cell progenitors at the tumor site enhances tumor responses to therapeutic PD-L1 and BRAF inhibition, Immunity, 44, 924, 10.1016/j.immuni.2016.03.012

Spranger, 2017, Tumor-residing Batf3 dendritic cells are required for effector T cell trafficking and adoptive T cell therapy, Cancer Cell, 31, 711, 10.1016/j.ccell.2017.04.003

Roberts, 2016, Critical role for CD103(+)/CD141(+) dendritic cells bearing CCR7 for tumor antigen trafficking and priming of T cell immunity in melanoma, Cancer Cell, 30, 324, 10.1016/j.ccell.2016.06.003

Twyman-Saint Victor, 2015, Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer, Nature, 520, 373, 10.1038/nature14292

Dovedi, 2014, Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade, Cancer Res, 74, 5458, 10.1158/0008-5472.CAN-14-1258

Demaria, 2005, Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer, Clin Cancer Res, 11, 728, 10.1158/1078-0432.728.11.2

Golden, 2013, An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer, Cancer Immunol Res, 1, 365, 10.1158/2326-6066.CIR-13-0115

De Henau, 2016, Overcoming resistance to checkpoint blockade therapy by targeting PI3Kgamma in myeloid cells, Nature, 539, 443, 10.1038/nature20554

Sivan, 2015, Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy, Science, 350, 1084, 10.1126/science.aac4255

Vetizou, 2015, Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota, Science, 350, 1079, 10.1126/science.aad1329

Routy, 2018, Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors, Science, 359, 91, 10.1126/science.aan3706

Gopalakrishnan, 2018, Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients, Science, 359, 97, 10.1126/science.aan4236

Ni, 2017, New checkpoints in cancer immunotherapy, Immunol Rev, 276, 52, 10.1111/imr.12524

Janakiram, 2017, The third group of the B7-CD28 immune checkpoint family: HHLA2, TMIGD2, B7x, and B7-H3, Immunol Rev, 276, 26, 10.1111/imr.12521

Pentcheva-Hoang, 2009, Negative regulators of T-cell activation: potential targets for therapeutic intervention in cancer, autoimmune disease, and persistent infections, Immunol Rev, 229, 67, 10.1111/j.1600-065X.2009.00763.x

Huard, 1995, CD4/major histocompatibility complex class II interaction analyzed with CD4- and lymphocyte activation gene-3 (LAG-3)-Ig fusion proteins, Eur J Immunol, 25, 2718, 10.1002/eji.1830250949

Xu, 2014, LSECtin expressed on melanoma cells promotes tumor progression by inhibiting antitumor T-cell responses, Cancer Res, 74, 3418, 10.1158/0008-5472.CAN-13-2690

Zhu, 2005, The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity, Nat Immunol, 6, 1245, 10.1038/ni1271

DeKruyff, 2010, T cell/transmembrane, Ig, and mucin-3 allelic variants differentially recognize phosphatidylserine and mediate phagocytosis of apoptotic cells, J Immunol, 184, 1918, 10.4049/jimmunol.0903059

Chiba, 2012, Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1, Nat Immunol, 13, 832, 10.1038/ni.2376

Huang, 2015, CEACAM1 regulates TIM-3-mediated tolerance and exhaustion, Nature, 517, 386, 10.1038/nature13848

Ndhlovu, 2012, Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity, Blood, 119, 3734, 10.1182/blood-2011-11-392951

Wang, 2011, VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses, J Exp Med, 208, 577, 10.1084/jem.20100619

Flies, 2014, Coinhibitory receptor PD-1H preferentially suppresses CD4(+) T cell-mediated immunity, J Clin Invest, 124, 1966, 10.1172/JCI74589

Schildberg, 2016, Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family, Immunity, 44, 955, 10.1016/j.immuni.2016.05.002

Chauvin, 2015, TIGIT and PD-1 impair tumor antigen-specific CD8(+) T cells in melanoma patients, J Clin Invest, 125, 2046, 10.1172/JCI80445

Johnston, 2014, The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function, Cancer Cell, 26, 923, 10.1016/j.ccell.2014.10.018

Joller, 2011, Cutting edge: TIGIT has T cell-intrinsic inhibitory functions, J Immunol, 186, 1338, 10.4049/jimmunol.1003081

Gao, 2017, VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer, Nat Med, 23, 551, 10.1038/nm.4308

Liu, 2015, Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses, Proc Natl Acad Sci U S A, 112, 6682, 10.1073/pnas.1420370112

Byrne, 2016, CD40 stimulation obviates innate sensors and drives T cell immunity in cancer, Cell Rep, 15, 2719, 10.1016/j.celrep.2016.05.058

Vonderheide, 2013, Agonistic CD40 antibodies and cancer therapy, Clin Cancer Res, 19, 1035, 10.1158/1078-0432.CCR-12-2064

Sznol, 2017, Pooled analysis safety profile of nivolumab and ipilimumab combination therapy in patients with advanced melanoma, J Clin Oncol, 35, 3815, 10.1200/JCO.2016.72.1167

Johnson, 2016, Fulminant myocarditis with combination immune checkpoint blockade, N Engl J Med, 375, 1749, 10.1056/NEJMoa1609214

Moslehi, 2018, Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis, Lancet, 391, 933, 10.1016/S0140-6736(18)30533-6

Coutzac, 2017, Colon immune-related adverse events: anti–CTLA-4 and anti-PD-1 blockade induce distinct immunopathological entities, J Crohns Colitis, 11, 1238, 10.1093/ecco-jcc/jjx081

Matsushita, 2012, Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting, Nature, 482, 400, 10.1038/nature10755

Overman, 2017, Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study, Lancet Oncol, 18, 1182, 10.1016/S1470-2045(17)30422-9

Miao, 2018, Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma, Science, 359, 801, 10.1126/science.aan5951

Freeman, 1993, Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation, Science, 262, 909, 10.1126/science.7694363

Freeman, 1993, Uncovering of functional alternative CTLA-4 counter-receptor in B7-deficient mice, Science, 262, 907, 10.1126/science.7694362

Krummel, 1995, CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation, J Exp Med, 182, 459, 10.1084/jem.182.2.459

Krummel, 1996, CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells, J Exp Med, 183, 2533, 10.1084/jem.183.6.2533

Lenschow, 1993, Expression and functional significance of an additional ligand for CTLA-4, Proc Natl Acad Sci U S A, 90, 11054, 10.1073/pnas.90.23.11054

Ishida, 1992, Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death, EMBO J, 11, 3887, 10.1002/j.1460-2075.1992.tb05481.x

Sheppard, 2004, PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3zeta signalosome and downstream signaling to PKCtheta, FEBS Lett, 574, 37, 10.1016/j.febslet.2004.07.083

Tseng, 2001, B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells, J Exp Med, 193, 839, 10.1084/jem.193.7.839

Chemnitz, 2004, SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation, J Immunol, 173, 945, 10.4049/jimmunol.173.2.945

Triebel, 1990, LAG-3, a novel lymphocyte activation gene closely related to CD4, J Exp Med, 171, 1393, 10.1084/jem.171.5.1393

Huard, 1997, Characterization of the major histocompatibility complex class II binding site on LAG-3 protein, Proc Natl Acad Sci U S A, 94, 5744, 10.1073/pnas.94.11.5744

Workman, 2002, Cutting edge: molecular analysis of the negative regulatory function of lymphocyte activation gene-3, J Immunol, 169, 5392, 10.4049/jimmunol.169.10.5392

Workman, 2005, Negative regulation of T cell homeostasis by lymphocyte activation gene-3 (CD223), J Immunol, 174, 688, 10.4049/jimmunol.174.2.688

Andreae, 2002, Maturation and activation of dendritic cells induced by lymphocyte activation gene-3 (CD223), J Immunol, 168, 3874, 10.4049/jimmunol.168.8.3874

Monney, 2002, Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease, Nature, 415, 536, 10.1038/415536a

Stanietsky, 2009, The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity, Proc Natl Acad Sci U S A, 106, 17858, 10.1073/pnas.0903474106

Yu, 2009, The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells, Nat Immunol, 10, 48, 10.1038/ni.1674

Levin, 2011, Vstm3 is a member of the CD28 family and an important modulator of T-cell function, Eur J Immunol, 41, 902, 10.1002/eji.201041136

Boles, 2009, A novel molecular interaction for the adhesion of follicular CD4 T cells to follicular DC, Eur J Immunol, 39, 695, 10.1002/eji.200839116

Stanietsky, 2013, Mouse TIGIT inhibits NK-cell cytotoxicity upon interaction with PVR, Eur J Immunol, 43, 2138, 10.1002/eji.201243072

Lines, 2014, VISTA is an immune checkpoint molecule for human T cells, Cancer Res, 74, 1924, 10.1158/0008-5472.CAN-13-1504

Wang, 2014, Disruption of the immune-checkpoint VISTA gene imparts a proinflammatory phenotype with predisposition to the development of autoimmunity, Proc Natl Acad Sci U S A, 111, 14846, 10.1073/pnas.1407447111

Yoshinaga, 1999, T-cell co-stimulation through B7RP-1 and ICOS, Nature, 402, 827, 10.1038/45582

McAdam, 2000, Mouse inducible costimulatory molecule (ICOS) expression is enhanced by CD28 costimulation and regulates differentiation of CD4+ T cells, J Immunol, 165, 5035, 10.4049/jimmunol.165.9.5035

Burmeister, 2008, ICOS controls the pool size of effector-memory and regulatory T cells, J Immunol, 180, 774, 10.4049/jimmunol.180.2.774

Fos, 2008, ICOS ligation recruits the p50alpha PI3K regulatory subunit to the immunological synapse, J Immunol, 181, 1969, 10.4049/jimmunol.181.3.1969

Nurieva, 2008, Generation of T follicular helper cells is mediated by interleukin-21 but independent of T helper 1, 2, or 17 cell lineages, Immunity, 29, 138, 10.1016/j.immuni.2008.05.009

Choi, 2011, ICOS receptor instructs T follicular helper cell versus effector cell differentiation via induction of the transcriptional repressor Bcl6, Immunity, 34, 932, 10.1016/j.immuni.2011.03.023

Maazi, 2015, ICOS:ICOS-ligand interaction is required for type 2 innate lymphoid cell function, homeostasis, and induction of airway hyperreactivity, Immunity, 42, 538, 10.1016/j.immuni.2015.02.007

Leconte, 2016, Inducible costimulator (ICOS) potentiates TCR-induced calcium flux by augmenting PLCgamma1 activation and actin remodeling, Mol Immunol, 79, 38, 10.1016/j.molimm.2016.09.022

Paterson, 1987, Antigens of activated rat T lymphocytes including a molecule of 50,000 Mr detected only on CD4 positive T blasts, Mol Immunol, 24, 1281, 10.1016/0161-5890(87)90122-2

Godfrey, 1994, Identification of a human OX-40 ligand, a costimulator of CD4+ T cells with homology to tumor necrosis factor, J Exp Med, 180, 757, 10.1084/jem.180.2.757

Gramaglia, 1998, Ox-40 ligand: a potent costimulatory molecule for sustaining primary CD4 T cell responses, J Immunol, 161, 6510, 10.4049/jimmunol.161.12.6510

Rogers, 2001, OX40 promotes Bcl-xL and Bcl-2 expression and is essential for long-term survival of CD4 T cells, Immunity, 15, 445, 10.1016/S1074-7613(01)00191-1

Zingoni, 2004, Cross-talk between activated human NK cells and CD4+ T cells via OX40-OX40 ligand interactions, J Immunol, 173, 3716, 10.4049/jimmunol.173.6.3716

Baumann, 2004, Functional expression of CD134 by neutrophils, Eur J Immunol, 34, 2268, 10.1002/eji.200424863

Song, 2004, The costimulation-regulated duration of PKB activation controls T cell longevity, Nat Immunol, 5, 150, 10.1038/ni1030

Nocentini, 1997, A new member of the tumor necrosis factor/nerve growth factor receptor family inhibits T cell receptor-induced apoptosis, Proc Natl Acad Sci U S A, 94, 6216, 10.1073/pnas.94.12.6216

Gurney, 1999, Identification of a new member of the tumor necrosis factor family and its receptor, a human ortholog of mouse GITR, Curr Biol, 9, 215, 10.1016/S0960-9822(99)80093-1

Kwon, 1999, Identification of a novel activation-inducible protein of the tumor necrosis factor receptor superfamily and its ligand, J Biol Chem, 274, 6056, 10.1074/jbc.274.10.6056

McHugh, 2002, CD4(+)CD25(+) immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor, Immunity, 16, 311, 10.1016/S1074-7613(02)00280-7

Shimizu, 2002, Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance, Nat Immunol, 3, 135, 10.1038/ni759

Hanabuchi, 2006, Human plasmacytoid predendritic cells activate NK cells through glucocorticoid-induced tumor necrosis factor receptor-ligand (GITRL), Blood, 107, 3617, 10.1182/blood-2005-08-3419

Esparza, 2006, Tumor necrosis factor receptor (TNFR)-associated factor 5 is a critical intermediate of costimulatory signaling pathways triggered by glucocorticoid-induced TNFR in T cells, J Biol Chem, 281, 8559, 10.1074/jbc.M512915200

Kwon, 1989, cDNA sequences of two inducible T-cell genes, Proc Natl Acad Sci U S A, 86, 1963, 10.1073/pnas.86.6.1963

Pollok, 1993, Inducible T cell antigen 4-1BB. Analysis of expression and function, J Immunol, 150, 771, 10.4049/jimmunol.150.3.771

Saoulli, 1998, CD28-independent, TRAF2-dependent costimulation of resting T cells by 4-1BB ligand, J Exp Med, 187, 1849, 10.1084/jem.187.11.1849

Futagawa, 2002, Expression and function of 4-1BB and 4-1BB ligand on murine dendritic cells, Int Immunol, 14, 275, 10.1093/intimm/14.3.275

Wilcox, 2002, Cutting edge: expression of functional CD137 receptor by dendritic cells, J Immunol, 168, 4262, 10.4049/jimmunol.168.9.4262

Banchereau, 1995, Functional CD40 antigen on B cells, dendritic cells and fibroblasts, Adv Exp Med Biol, 378, 79, 10.1007/978-1-4615-1971-3_16

Garside, 1998, Visualization of specific B and T lymphocyte interactions in the lymph node, Science, 281, 96, 10.1126/science.281.5373.96

Ahonen, 2002, The CD40-TRAF6 axis controls affinity maturation and the generation of long-lived plasma cells, Nat Immunol, 3, 451, 10.1038/ni792

Mackey, 2003, Distinct contributions of different CD40 TRAF binding sites to CD154-induced dendritic cell maturation and IL-12 secretion, Eur J Immunol, 33, 779, 10.1002/eji.200323729

Goodwin, 1993, Molecular and biological characterization of a ligand for CD27 defines a new family of cytokines with homology to tumor necrosis factor, Cell, 73, 447, 10.1016/0092-8674(93)90133-B

Gravestein, 1993, Cloning and expression of murine CD27: comparison with 4-1BB, another lymphocyte-specific member of the nerve growth factor receptor family, Eur J Immunol, 23, 943, 10.1002/eji.1830230427

Akiba, 1998, CD27, a member of the tumor necrosis factor receptor superfamily, activates NF-kappaB and stress-activated protein kinase/c-Jun N-terminal kinase via TRAF2, TRAF5, and NF-kappaB-inducing kinase, J Biol Chem, 273, 13353, 10.1074/jbc.273.21.13353

Hendriks, 2000, CD27 is required for generation and long-term maintenance of T cell immunity, Nat Immunol, 1, 433, 10.1038/80877

Hayakawa, 2006, CD27 dissects mature NK cells into two subsets with distinct responsiveness and migratory capacity, J Immunol, 176, 1517, 10.4049/jimmunol.176.3.1517